FDA accepts NDA for priority review of TMC125.
D019380:Anti-HIV Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D009570:Nitriles; D011724:Pyridazines / Q000627:therapeutic use; D011743:Pyrimidines; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
D019380:Anti-HIV Agents; D009570:Nitriles; D011724:Pyridazines; D011743:Pyrimidines; C451734:etravirine